THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q1 2018 13F Holders as of 31 Mar 2018

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
107.2%
Total 13F principal
$196,713,971
Principal change
+$12,598,367
Total reported market value
$212,680,430
Number of holders
35
Value change
+$14,289,892
Number of buys
15
Number of sells
17

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q1 2018

As of 31 Mar 2018, THERAVANCE INC - CORPORATE OBLIG was held by 35 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $196,713,971 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, CNH PARTNERS LLC, OAKTREE CAPITAL MANAGEMENT LP, CALAMOS ADVISORS LLC, LAZARD ASSET MANAGEMENT LLC, AMUNDI PIONEER ASSET MANAGEMENT INC, ADVENT CAPITAL MANAGEMENT /DE/, SSI INVESTMENT MANAGEMENT INC, AMERIPRISE FINANCIAL INC, and Castle Creek Arbitrage, LLC. This page lists 35 institutional bondholders reporting positions for the Q1 2018 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.